Skip to content
MARKETS / NASDAQ / AKAN
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Akanda Corp. AKAN

6 fiscal years on record · USD · FY2024 reported · SEC filings only
$836,664
▲ 97.5% YoY
$-4.1M
$-6.1M
In brief

What this company does

Akanda discontinued its Canmart operations and moved to cultivating cannabis products at its British Columbia facilities, where it had not yet begun cultivation operations. Health Canada approved a hemp license for its subsidiary 1468243 B.C. LTD. As of June 8, 2026 it had two part-time executives and six full-time employees, none of them represented by labor unions or subject to collective bargaining agreements. Its subsidiary First Towers develops towers and operates a 700+km fiber optic network in the wireless market of Mexico. First Towers was incorporated in the province of British Columbia, Canada on February 24, 2017 under the name Canadian Towers and Fiber Optics Inc., and later took the name First Towers & Fiber Corp.

Written from the business description in AKANDA CORP.'s annual report to the U.S. Securities and Exchange Commission, filed 9 June 2026. Every sentence was checked against that document before publication.

Growth
USD 836,664.00
Revenue, FY2024 · full 6-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.8 · Net income -4.1
-20M201920202021202220232024
Compound annual growth
+172.3%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−490 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -523.8% · Net -489.6%
-50000%-100000%201920202021202220232024
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -6.1
-4M-8M201920202021202220232024

Total assetsUSD 7.9M
CashUSD 3.8M
Current ratio1.39×

Not available: we don't have the total debt figure for this period.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202420232022202120202019
Revenue $B0.00.00.00.00.0·
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0··
EPS, diluted $−3.93−573.11−3.86−0.50−0.18−0.11
Dividend / sh $······
Payout %······
ROE %······

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 26 reconciliationsAUDITED

Reconciled in 5 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 69 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A6
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2019

Share this section

Download image